Posters

Trehalose 3% (Thealoz®) therapy in dry eye syndrome treatment after keratorefractive surgery

Poster Details

First Author: A.Titov RUSSIA

Co Author(s):    I. Panova   D. Mirsaitova                 

Abstract Details

Purpose:

To analyze the efficacy of artificial tear drops Thealoz® (trehalose 3%) in correction of dry eye syndrome (DES) after keratorefractive surgery based on instrumental monitoring of the eye surface condition.

Setting:

St. Petersburg branch of S. Fyodorov Eye Microsurgery Federal State Institution, 21 Yaroslav Gasheka str., St. Petersburg, Russian Federation, 192283

Methods:

The study included 20 patients (40 eyes) who underwent a keratorefractive surgery and were prescribed instillations of artificial tear drops Thealoz® for dry eye syndrome treatment. Patients were divided into 2 groups: the 1st group consisted of 10 patients who underwent ReLEx SMILE surgery, the 2nd group – 10 patients after FEMTO LASIK. The efficacy of treatment was evaluated in 1 and 3 months after surgery using conventional instrumental monitoring: tear break-up time (Norn’s test), tear film osmolarity test and OCT-meniscometry.

Results:

Norn test increased from 11.16±0.38sec.to 12.95±0.24 (р≤0,05) and 13.85±0.03 sec.(р≤0,05) by1- and 3-months’ time after treatment regardless type of surgery. Which correlated with progressive decrease of tears osmolarity from 317.29 ± 1.39 mOsm/L to 308.00 ± 0.79 mOsm/L (р≤0,05) in a month and in 3 months after treatment-301.75 ± 0.27 mOsm/L (р≤0,05). There was also improvement in OCT - meniscometry parameters such as a significant height increase from 310,89±9,66 µm to322,66±5,18 µm and depth increase from 217,72±1,65 µm to 227,63±0,28 µm in 1- and 3-months’ time after of using Thealoz® (р≤0,05).Study groups(p≤0.05)had similar changes.

Conclusions:

Thealoz® efficacy is proved for dry eye syndrome treatment after keratorefraction operations according to results of the instrumental monitoring. The obtained results clearly demonstrate that Thealoz® helps not only to increase the stability of the tear film, but also to restore the tear osmolarity values and OCT-morphometric indicators of the tear meniscus. Absence of preservative, good tolerance and efficacy justify the expediency of its use in pathogenetic therapy of dry eye syndrome in patients after keratorefractive operations.

Financial Disclosure:

None